Skip to Content

Perrigo Co PLC PRGO

Morningstar Rating
$27.26 +0.32 (1.19%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Perrigo Earnings: Tumbled Start to 2024 as Volume Loss Worsens and Margins Shrink

No-moat Perrigo reported disappointing first-quarter results that came in below our expectations, Total sales of $1.1 billion were down 8.4% year over year with 4.3% loss from infant formula business and 3.6% loss from portfolio optimization and minor offset from base business growth. After updating our model and baking in slightly lowered outlook for the year with slight offset from time value of money impact, we lightly trim our fair value estimate to $36 per share from $37.

Price vs Fair Value

PRGO is trading at a 620% premium.
Price
$26.94
Fair Value
$11.00
Uncertainty
Medium
1-Star Price
$85.20
5-Star Price
$84.10
Economic Moat
Tppy
Capital Allocation
Zrwjlmrs

Bulls Say, Bears Say

Bulls

Perrigo is now more tapped in to the higher-margin branded consumer health market, and this should act as tailwind to the top and bottom lines in future.

Bears

By expanding its business to focus more on branded products, Perrigo now faces stiffer competition from larger consumer healthcare product manufacturers.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRGO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$26.94
Day Range
$26.5727.27
52-Week Range
$25.7740.28
Bid/Ask
$27.00 / $29.09
Market Cap
$3.72 Bil
Volume/Avg
1.1 Mil / 1.6 Mil

Key Statistics

Price/Earnings (Normalized)
11.13
Price/Sales
0.80
Dividend Yield (Trailing)
4.08%
Dividend Yield (Forward)
4.10%
Total Yield
4.08%

Company Profile

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
9,140

Competitors

Valuation

Metric
PRGO
HLN
PG
Price/Earnings (Normalized)
11.1318.5425.57
Price/Book Value
0.781.868.00
Price/Sales
0.802.794.92
Price/Cash Flow
7.6017.6120.37
Price/Earnings
PRGO
HLN
PG

Financial Strength

Metric
PRGO
HLN
PG
Quick Ratio
0.920.630.40
Current Ratio
1.811.040.64
Interest Coverage
0.364.9420.66
Quick Ratio
PRGO
HLN
PG

Profitability

Metric
PRGO
HLN
PG
Return on Assets (Normalized)
3.06%13.82%
Return on Equity (Normalized)
6.94%35.61%
Return on Invested Capital (Normalized)
5.38%20.62%
Return on Assets
PRGO
HLN
PG
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
DlsfqytzMzmqlc$81.1 Bil
Zoetis Inc Class A
ZTS
SmkqmvfnkThpn$80.7 Bil
Haleon PLC ADR
HLN
NjyyclmLtrx$38.6 Bil
Viatris Inc
VTRS
DptlfpnrjTgjkz$12.5 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
VwhvlqmvSskw$12.1 Bil
Catalent Inc
CTLT
VnvptqqbqVnhgp$10.2 Bil
Curaleaf Holdings Inc
CURLF
VxcmzcpmfTwzx$3.4 Bil
Prestige Consumer Healthcare Inc
PBH
WbxncwgXpcghln$3.3 Bil
Green Thumb Industries Inc
GTBIF
LwmhygcmyGjw$2.9 Bil

Sponsor Center